Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$2.42 USD
-0.03 (-1.22%)
Updated Jul 2, 2024 04:00 PM ET
After-Market: $2.42 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth D Momentum F VGM
Aquestive Therapeutics (AQST) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$9.14 | $13.00 | $7.00 | 273.06% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Aquestive Therapeutics comes to $9.14. The forecasts range from a low of $7.00 to a high of $13.00. The average price target represents an increase of 273.06% from the last closing price of $2.45.
Analyst Price Targets (7 )
Broker Rating
Aquestive Therapeutics currently has an average brokerage recommendation (ABR) of 1.14 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.13 a month ago based on eight recommendations.
Of the seven recommendations deriving the current ABR, six are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 85.71% and 14.29% of all recommendations. A month ago, Strong Buy made up 87.5%, while Buy represented 12.5%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/AQST.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 7 | 7 | 6 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.14 | 1.14 | 1.13 | 1.13 | 1.14 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/26/2024 | JMP Securities | Jason N Butler | Strong Buy | Strong Buy |
5/10/2024 | SVB Securities | Roanna Ruiz | Not Available | Strong Buy |
5/9/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/11/2024 | Piper Sandler | David Amsellem | Strong Buy | Strong Buy |
3/28/2024 | Raymond James | Gary Nachman | Moderate Buy | Moderate Buy |
3/8/2024 | H.C. Wainwright & Co. | Raghuram Selvaraju | Strong Buy | Strong Buy |
3/7/2024 | Lake Street Capital Markets | Thomas Flaten | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.14 |
ABR (Last week) | 1.14 |
# of Recs in ABR | 7 |
Average Target Price | $9.14 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 104 of 252 |
Current Quarter EPS Est: | -0.11 |